Galantamine Hydrobromide Market Report 2025

The galantamine hydrobromide market size has grown strongly in recent years. It will grow from $0.67 billion in 2024 to $0.73 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to rising investments, growing elderly population, increasing diagnosis rate, growing awareness of neurodegenerative illnesses, and increasing life expectancy.

The galantamine hydrobromide market size is expected to see strong growth in the next few years. It will grow to $1.06 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to increasing clinical trials, increasing importance of early diagnosis, rising incidence of Alzheimer's, growing research funding and drug development for Alzheimer's disease, and growing emphasis on research and development. Major trends in the forecast period include collaborations between pharmaceutical companies and research institutions, advancements in treatment, expansion of the indications for galantamine hydrobromide through ongoing clinical trials, personalized medicine, advancements in biotechnology and pharmaceutical research.

The forecast of 9.7% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade restrictions could hinder Alzheimer's treatment by inflating prices of this cholinesterase inhibitor active pharmaceutical ingredient and extended-release capsule components sourced from Hungary and Poland, reducing dementia medication adherence and raising neurology care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of Alzheimer’s disease is expected to drive the expansion of the galantamine hydrobromide market over the forecast period. Alzheimer’s disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes, often impairing the ability to carry out everyday activities. The incidence of Alzheimer’s is rising due to the aging global population, as the likelihood of developing the disease increases significantly with age due to accumulated brain changes and genetic predisposition. Galantamine hydrobromide is used to manage Alzheimer’s symptoms by increasing acetylcholine levels through inhibition of its breakdown, thereby helping to slow cognitive decline and enhance memory in patients with reduced neurotransmitter function. For instance, in August 2024, the Centers for Disease Control and Prevention (CDC) reported that the number of individuals living with Alzheimer’s in the U.S. is expected to rise from 6.9 million to nearly 14 million by 2060. Therefore, the increasing prevalence of Alzheimer’s disease is driving the growth of the galantamine hydrobromide market.

Leading companies in the galantamine hydrobromide market are developing next-generation acetylcholinesterase inhibitors (AChEIs) to improve treatment outcomes, reduce side effects, and promote better patient adherence. These advanced AChEIs aim to enhance cognitive performance in neurodegenerative conditions by improving bioavailability while minimizing adverse effects. For example, in July 2024, Alpha Cognition Inc., a Canada-based biopharmaceutical company, received U.S. FDA approval for ALPHA-1062 (Zunveyl), a prodrug version of galantamine for mild to moderate Alzheimer’s disease. ALPHA-1062 features improved safety and bioavailability compared to traditional formulations. Unlike standard galantamine, it is absorbed in the small intestine as an inert substance, avoiding early interaction with acetylcholinesterase in the gastrointestinal system. The addition of a benzyl ester helps reduce local neuronal overstimulation, lessens gastrointestinal side effects, and enhances bioavailability. Once metabolized in the liver, ALPHA-1062 becomes active and delivers galantamine efficiently to the brain through the bloodstream.

In April 2024, Essential Pharma Group Limited, a UK-based specialty pharmaceutical company, acquired the oral capsule formulation of Reminyl (galantamine hydrobromide) from Janssen Pharmaceutica NV for an undisclosed amount. This acquisition ensures the continued availability of and access to galantamine hydrobromide treatment for Alzheimer’s patients. Janssen Pharmaceutica, a Belgium-based pharmaceutical company, is known for developing therapies across several fields including neurology, infectious diseases, immunology, oncology, and cardiology.

Major players in the galantamine hydrobromide market are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Ajinomoto Co. Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Jubilant Pharmova Limited, Cohance Lifesciences Limited, Indena S.p.A., ScinoPharm Taiwan Ltd., Estechpharma Co. Ltd., Nortec Química S.A., Metrochem API Private Limited, Sanochemia Pharmazeutika AG, Pellets Pharma Limited, Midas Pharma GmbH, Jubilant Generics, Capital Farma, Wuhan Shiji Pharmaceutical Co. Ltd., Credo Life Sciences Pvt. Ltd.

North America was the largest region in the galantamine hydrobromide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in galantamine hydrobromide report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the galantamine hydrobromide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The galantamine hydrobromide market consists of sales of extended-release capsules, injectable solutions, transdermal patches, sublingual drops, and powder for compounding. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The galantamine hydrobromide market research report is one of a series of new reports that provides galantamine hydrobromide market statistics, including galantamine hydrobromide industry global market size, regional shares, competitors with a galantamine hydrobromide market share, detailed galantamine hydrobromide market segments, market trends and opportunities, and any further data you may need to thrive in the galantamine hydrobromide industry. This galantamine hydrobromide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Galantamine hydrobromide is a pharmaceutical compound used to treat mild to moderate Alzheimer’s disease and other memory-related conditions. As an acetylcholinesterase inhibitor, it works by increasing acetylcholine levels in the brain, which improves nerve signal transmission and cognitive function. Galantamine hydrobromide helps slow cognitive decline and enhances memory, attention, and overall mental function in patients with neurodegenerative disorders.

The main galantamine hydrobromide products include tablets, capsules, and oral solutions. Tablets are solid forms of medicine taken orally, where they dissolve in the digestive system to release the active ingredients. Galantamine hydrobromide is used for treating Alzheimer's disease, enhancing cognitive function, and other purposes by various end-users, including hospitals, research institutions, homecare settings, and long-term care facilities.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.